STERIS delivered Q1 results that met Wall Street’s revenue expectations, with the market reacting positively to the company’s performance. Management pointed to steady procedure volume growth in the U.S. and continued expansion in its Healthcare and Life Sciences segments as key drivers. CEO Dan Carestio cited strong service revenue, improved consumables growth, and a stabilizing capital equipment business, while also acknowledging external pressures such as inflation and tariffs. Notably, severe winter weather disruptions impacted procedural volumes and service activity, particularly in the AST (Applied Sterilization Technologies) segment.
Is now the time to buy STE? Find out in our full research report (it’s free for active Edge members).
STERIS (STE) Q1 CY2026 Highlights:
- Revenue: $1.59 billion vs analyst estimates of $1.59 billion (7.3% year-on-year growth, in line)
- Adjusted EPS: $2.83 vs analyst expectations of $2.85 (0.7% miss)
- Adjusted EBITDA: $462.2 million vs analyst estimates of $454.6 million (29.1% margin, 1.7% beat)
- Adjusted EPS guidance for the upcoming financial year 2027 is $11.20 at the midpoint, beating analyst estimates by 1.1%
- Operating Margin: 19.9%, up from 14.6% in the same quarter last year
- Constant Currency Revenue rose 5% year on year, in line with the same quarter last year
- Market Capitalization: $20.8 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From STERIS’s Q1 Earnings Call
- Brett Fishbin (KeyBanc): Asked about the drivers behind margin expansion guidance and how inflation, tariffs, and operational improvements factor in. CEO Dan Carestio emphasized operational improvements and higher-margin consumables, while CFO Karen Burton explained that tariffs should remain stable and energy/freight costs are accounted for.
- Michael Matson (Needham & Company): Queried about USMCA (United States-Mexico-Canada Agreement) renegotiation risk and ethylene oxide (EO) regulatory changes. Burton said guidance assumes no USMCA disruption, while Carestio said EO regulatory rollbacks have minimal financial impact due to prior facility investments.
- David Turkaly (Citizens): Inquired about the logic behind recent M&A and the $1 billion share buyback authorization. Carestio explained the two recent acquisitions were strategic and impactful for Healthcare, while Burton discussed the measured approach to buybacks due to withholding tax considerations.
- Steven Etoch (Stephens): Sought color on AST segment volume trends and capital equipment backlog progression. Carestio noted weather disruptions and med tech customer inventory reductions are impacting AST, while capital equipment backlog was described as within normal cyclical patterns.
- Jason Bednar (Piper Sandler): Asked about buyback flexibility and supply chain resilience. Burton indicated buyback pacing will be guided by cash position and tax costs, while Carestio stressed supply chain investments have improved resilience versus previous years.
Catalysts in Upcoming Quarters
Looking ahead, the StockStory team will monitor (1) the pace of recovery in the AST segment as med tech customer inventories normalize and weather effects dissipate, (2) execution of automation and AI initiatives in service workflows for Healthcare and Life Sciences, and (3) the integration and revenue contribution from recent tuck-in acquisitions. We will also track management’s ability to maintain margin expansion amid ongoing cost pressures.
STERIS currently trades at $212.28, up from $201.85 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).
The Best Stocks for High-Quality Investors
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
